@misc{oai:u-fukui.repo.nii.ac.jp:00020624,
 author = {YOSHIDA, Yoshio and KUROKAWA, Tetsuji and SAWAMURA, Yoko and SHINAGAWA, Akiko and OKAZAWA, Hidehiko and FUJIBAYASHI, Yasuhisa and KOTSUJI, Fumikazu},
 month = {Mar},
 note = {Background. The positron emission tomography (PET) with F18 17β-estradiol (FES) has good imaging for assessment of estrogen receptor in breast cancer. Case. We report on a 30-year-old woman who desired to preserve her fertility with well-differentiated endometrial adenocarcinoma. Before hormone treatment was started, FES-PET showed increased uptake of endometrium, magnetic resonance imaging (MRI) showed thickness and F- 18 fluorodeoxyglucose (FDG)-PET showed increased uptake. FES-PET after 3 months showed remaining FES uptake, but there were no abnormal findings on MRI and FDG-PET. Hysteroscopy showed remaining adenocarcinoma. After additional treatment, FES-PET showed a therapeutic response, and hysteroscopy showed no abnormal finding. Conclusions. To our knowledge, this is the first report that FES-PET has the potential to provide more useful information than did FDG-PET about the hormone therapy.},
 title = {The positron emission tomography with F18 17β-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer},
 year = {2007}
}